Stock Analiz

Teva Pharmaceutical Industries Ltd. (TEVA) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Teva Pharmaceutical Industries’s revenue went from $16.9B in fiscal 2019 to $17.3B in fiscal 2025, growth of about 0.4% a year.

Net income in fiscal 2025 was $1.4B, a net margin of 8.2%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $17.2B and net income $506M.

Free cash flow was $1.1B in fiscal 2025 and positive in 7 of the 7 years shown.

Revenue, profit and cash flow by year

Revenue
2019: $16.9B20192020: $16.7B20202021: $15.9B20212022: $14.9B20222023: $15.8B20232024: $16.5B20242025: $17.3B2025$17.3B
Net income
2019: -$999M20192020: -$4.0B20202021: $417M20212022: -$2.4B20222023: -$559M20232024: -$1.6B20242025: $1.4B2025$1.4B
Free cash flow
2019: $223M20192020: $638M20202021: $236M20212022: $1.0B20222023: $842M20232024: $749M20242025: $1.1B2025$1.1B
EPS (diluted)
2019: $-0.8620192020: $-3.4220202021: $0.3620212022: $-2.1020222023: $-0.4820232024: $-1.4020242025: $1.212025$1.21

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$17.2B$17.3B$16.5B$15.8B$14.9B$15.9B$16.7B$16.9B
Gross profit$9.2B$8.9B$8.1B$7.6B$7.0B$7.6B$7.7B$7.5B
Operating income$1.4B$2.2B-$303M$433M-$2.2B$1.7B-$3.6B-$443M
Net income$506M$1.4B-$1.6B-$559M-$2.4B$417M-$4.0B-$999M
EPS (diluted)$0.43$1.21$-1.40$-0.48$-2.10$0.36$-3.42$-0.86
R&D$1.8B$1.0B$998M$953M$98M$967M$997M$1.0B
Revenue growth—+4.3%+4.4%+6.2%−6.0%−4.7%−1.4%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow$1.8B$1.6B$1.2B$1.4B$1.6B$798M$1.2B$748M
Capital spending-$534M-$501M-$498M-$526M-$548M-$562M-$578M-$525M
Free cash flow$1.2B$1.1B$749M$842M$1.0B$236M$638M$223M
Dividends paid————————
Buybacks————————
Stock-based pay$172M$157M$123M$121M$124M$119M$129M$119M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$3.6B$3.3B$3.2B$2.8B$2.2B$2.2B$2.0B
Debt—$17.2B$18.2B$20.3B$21.7B$23.6B$26.1B$27.0B
Equity—$7.9B$5.4B$7.5B$7.8B$10.3B$10.0B$14.0B
Total assets—$40.7B$39.3B$43.5B$44.0B$47.7B$50.6B$57.5B
Shares (diluted)1.18B1.17B1.17B1.17B1.17B1.17B1.17B1.17B

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin53.5%51.8%48.7%48.2%46.7%47.8%46.4%44.6%
Operating margin8.3%12.5%-1.8%2.7%-14.7%10.8%-21.4%-2.6%
Net margin2.9%8.2%-9.9%-3.5%-16.4%2.6%-23.9%-5.9%
FCF margin7.2%6.7%4.5%5.3%7.0%1.5%3.8%1.3%
ROIC—6.8%-1.0%1.5%-5.9%3.4%-9.5%-0.8%
ROE—17.8%-30.5%-7.4%-31.3%4.1%-39.8%-7.1%

Frequently asked questions

What is Teva Pharmaceutical Industries’s annual revenue?

$17.3B in fiscal 2025 and $17.2B over the twelve months to September 30, 2026.

How much profit does Teva Pharmaceutical Industries make?

Net income was $1.4B in fiscal 2025 (net margin 8.2%).

Is Teva Pharmaceutical Industries’s revenue growing?

Yes: revenue rose 4.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.